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Murine gammaherpesvirus 68 (MHV-68) infection of mice represents a viable small-animal model for the
study of gammaherpesvirus pathogenesis. MHV-76 is a deletion mutant of MHV-68, which lacks four MHV-
68-specific genes (M1 to M4) and eight viral tRNA-like sequences at the 5 end of the genome. These genes are
implicated in latency and/or immune evasion. Consequently, MHV-76 is attenuated in the acute phase of in vivo
infection with respect to MHV-68. Little is known about the role of M4 in viral infection, except that it is
expressed as an immediate-early/early transcript during lytic replication of MHV-68 in vitro. To elucidate the
contribution M4 makes to in vivo pathogenesis, we created a novel MHV-76 mutant (MHV-76inM4), in which
the region of MHV-68 coding for M4 and accompanying putative promoter elements were inserted into the 5
region of the MHV-76 genome. The growth of MHV-76inM4 in vitro was indistinguishable from that of MHV-76
and MHV-68. However, virus titers from MHV-76inM4-infected BALB/c mice were significantly increased with
respect to MHV-76 at early times in the lung. In addition, at days 17 and 21 postinfection, there was a
significant elevation in latent viral load in splenocytes of MHV-76inM4-infected mice compared to MHV-76.
Like MHV-76-infected mice, MHV-76inM4-infected mice display no evidence of overt splenomegaly, a finding
characteristic of MHV-68 infection. M4 expression in vivo was detectable during productive infection in the
lung and during the establishment of latency in the spleen, but in general M4 was not detectable during
long-term latency (day 100 postinfection).
Murine gammaherpesvirus 68 (MHV-68) is a well-estab-
lished small-animal model for the study of gammaherpesvirus
pathogenesis. MHV-68 infects inbred and outbred mice and,
after intranasal administration, undergoes productive infection
within lung epithelia, followed by lifelong latent infection. B
lymphocytes within the spleen comprise the major reservoir of
latent virus after intranasal infection (9, 27) although, like Kapo-
si’s sarcoma-associated herpesvirus, latent virus is detectable
within several other cell types, specifically dendritic cells, macro-
phages/monocytes, and lung epithelia (8, 21, 35). After the initial
detection of latently infected cells, the splenic viral latent load
continues to increase and then begins to decrease after it reaches
a peak at approximately 14 days postinfection (p.i.). We refer to
this stage of infection as acute-phase latency. During acute-phase
latency, overt splenomegaly is evident, a process dependent on
host (CD4 T cells) and viral factors (13, 25).
A related and previously characterized murid herpesvirus,
MHV-76, replicates equivalently to MHV-68 in vitro. How-
ever, MHV-76 is phenotypically distinguishable from MHV-68
after infection of immunocompetent mice. Lytic replication in
the lung differs significantly from MHV-68, since MHV-76
displays accelerated clearance and an increased inflammatory
infiltrate. Acute-phase splenic latency is also affected, with
peak latency reduced 50-fold with respect to MHV-68. Sig-
nificantly, splenomegaly is profoundly reduced in MHV-76-
infected mice. Macrae et al. (13) have confirmed this altered
phenotype of MHV-76 is the result of a 9,538-bp deletion at
the left terminus of MHV-68. In MHV-68, this 9,538-bp en-
compasses four open reading frames (ORFs; M1 to M4) and
eight viral tRNA-like sequences. This locus represents a cluster
of MHV-68-specific genes (possibly with latency-associated or
immunoregulatory functions), a genomic structure akin to
other characterized gammaherpesviruses, where virus-specific
genes are interspersed between gene blocks conserved among
gammaherpesviruses (31). Aside from this deletion, the left
termini of the MHV-76 and MHV-68 genomes are effectively
identical, but for one amino acid substitution and a trivial
discrepancy between terminal repeats. Reinsertion of the de-
leted 9,538 bp into MHV-76 restored the in vivo phenotype to
that of MHV-68 (13). Furthermore, an independently isolated
MHV-68 mutant, with a similar deletion to that of MHV-76,
displays a similar defect in splenic latency (4), underscoring the
contribution this locus at the left terminus of MHV-68 makes
to in vivo pathogenesis.
Data concerning the involvement of these MHV-68-specific
elements during in vivo infection remains limited. Thus far,
only one gene remains functionally characterized: M3 encodes
a broad-spectrum chemokine-binding protein that is expressed
during lytic replication and persistence (16, 30). Recombinant
MHV-68 mutants containing targeted loss-of-function muta-
tions provide data on the contribution of virus-specific ORFs
to in vivo pathogenesis. A deletion mutant lacking the M3 gene
suggests an important role for M3 in the maintenance of a
normal splenic latent load (2), although another deletion mu-
tant did not reproduce this phenotype but did demonstrate a
role for M3 in the modulation of the inflammatory response
after intracranial infection (29). Similarly, M1 has been impli-
cated in the control of reactivation (5), and a virus deficient in
functional M2 protein shows a major defect in splenic latency
(11).
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Little is known about the properties of the M4 gene except
that it is expressed as an immediate-early transcript during lytic
infection in vitro and that expression in vivo has been detected
during lytic infection but not during long-term persistence (6,
32). Considering the genomic location of M4 and that it is
dispensable for in vitro replication (13), it is likely that the M4
gene encodes a protein that is involved during latency or has
some immunomodulatory role during infection in vivo. The
current experiments used a novel approach to assess the con-
tribution M4 makes to MHV-68 pathogenesis in vivo, utilizing
a recombinant MHV-76 mutant expressing the M4 gene under
the control of its native promoter. This recombinant virus
demonstrates that M4 influences productive infection in the
lung and acute-phase latency within the spleen. To our knowl-
edge, this is the first report of a role for the M4 gene product
in the pathogenesis of a MHV-68 infection.
MATERIALS AND METHODS
Virus stocks and mouse infections. Virus stocks of MHV-68 and MHV-76
were prepared by infection of BHK-21 cells with MHV-68 clone g2.4 (1, 7) or
MHV-76 (1, 13) at a low multiplicity of infection (MOI; 0.001 PFU/cell) as
previously described (23). Viral DNA used for electroporation, sequencing, and
Southern analysis was extracted from intact purified virions as described previ-
ously (7). Female BALB/c mice were purchased from B&K Universal (Hull,
United Kingdom) and were infected at 4 weeks of age. All mice were infected
intranasally under halothane anesthesia by administration of 4  105 PFU of
virus suspended in 40 l of sterile phosphate-buffered saline. At specific times
p.i., mice were euthanized by CO2 asphyxiation, and organs were harvested. Lung
tissue was frozen at 70°C until assays were performed.
Analysis of infected tissues. For determining levels of preformed infectious
virus, the method described by Sunil-Chandra et al. (23) was used. Briefly, tissues
were homogenized in Glasgow medium, supplemented with 10% newborn calf
serum, 100 U of penicillin/ml, 100 U of streptomycin/ml, 2 mM L-glutamine, and
subjected to one freeze-thaw cycle. Plaque assays to detect preformed virus were
performed as previously described (23) on BHK-21 monolayers. An ex vivo
reactivation assay was utilized to detect latent virus within splenocytes, as de-
scribed previously (23). Briefly, splenocytes were counted, and specific dilutions
incubated with a susceptible monolayer (BHK-21 cells). Reactivating virus was
calculated from the total number of countable plaques minus the contribution
from preformed infectious virus. Preformed infectious virus was determined by
subjecting splenocytes to one freeze-thaw cycle prior to titration by plaque assay.
No preformed infectious virus was detectable from any splenocyte sample after
day 5 p.i.
Generation of recombinant viruses. MHV-76inM4 was generated by cotrans-
fection of BHK-21 cells with MHV-76 DNA and digested plasmid DNA. The
appropriate plasmid was generated by subcloning an MHV-68 terminal repeat
fragment (22) into the PstI site in the polylinker region of pUC18. A defined
region of the MHV-68 genome encompassing the M4 ORF (nucleotides [nt]
7414 to 10914, accession no. U97553) was inserted downstream between the
BamHI and EcoRI sites. To facilitate directional subcloning of the M4 fragment
into pUC18, restriction endonuclease sites were added to the M4 fragment of
MHV-68 during PCR amplification. PCR was performed by using MHV-68
DNA as a template in the presence of 10 U of Pfu turbo polymerase (Strat-
agene), Pfu Turbo polymerase buffer (Stratagene), 100 M deoxynucleoside
triphosphate (dNTP), and 50 pmol of each of the following oligonucleotides:
5-GCGCGGATCCCATGTGCTACCTCTGTGG-3 (nt 7414 to 7432) and 5-
GCGCGAATTCGTACCGTCTGAGTGACTG-3 (nt 10914 to 10897). The for-
ward primer introduced a BamHI site (underlined) within the PCR product, and
the reverse primer introduced an EcoRI site (underlined). The italicized se-
quence represents sequence not found in the MHV-68 template DNA being
amplified. Before electroporation, the plasmid was digested with HindIII and
EcoRI (excising both the terminal repeat and M4 insert on the same fragment)
and purified by phenol-chlorophorm extraction and ethanol precipitation. After
electroporation of BHK-21 cells with MHV-76 DNA and digested plasmid DNA,
the transfected BHK-21 cells were seeded into 96-well plates. Wells containing
single plaques after 5 days of incubation were harvested, and half the volume of
cell suspension was pelleted, resuspended in 100 l of sterile phosphate-buffered
saline, and subjected to overnight digestion with proteinase K at 56°C. Proteinase
K was heat inactivated at 95°C for 10 min, and 10 l of the sample was analyzed
by PCR for the presence of M4 and ORF50. The M4 PCR utilized the primer
pair M4AFor (5-GCGCGGATCCGACACCTGGAGAAGATGATGATATT
C-3; nt 8616 to 8637) and M4ARev (5-CGCGAATTCGGCAGTCGCATAAC
CATGTCCACG-3; nt 9176 to 9155). The ORF50 PCR utilized the primer pair
ORF50For (5-ATGGCACATTTGCTGCAGAAC-3; nt 68483 to 68503) and
ORF50Rev (5-ACGGCGCCTGTGTACTCAA-3; nt 68838 to 68820). PCRs
were setup by using 5 U of Taq DNA polymerase (Invitrogen) per reaction in the
presence of 100 M dNTP, 3 mM MgCl2, 50 pmol of each primer, and Taq DNA
polymerase buffer (Invitrogen). The cycling parameters were the same for both
primer pairs: 94°C for 45 s, 56°C for 45 s, and 72°C for 60 s for 40 cycles, with a
final extension at 72°C for 7 min. Single plaque isolates positive for M4 and
ORF50 by PCR were diluted and reseeded onto BHK-21 monolayers within
96-well plates. After five rounds of single-plaque selection, isolates were
screened for wild-type MHV-76 contamination by PCR. Genomic rearrange-
ments were confirmed by sequencing of purified viral DNA, and Southern anal-
ysis was performed according to established procedures (19) with 32P-labeled
probes produced from a fragment of M4 (nt 8616 to 9176) and the HindIIIG
fragment of MHV-68 (nt 11099 to 16237). Sequencing was carried out with
IRD800-modified primers on a Li-Cor automated sequencer.
A revertant virus of MHV-76inM4 was produced by cotransfection of purified
MHV-76inM4 DNA with the cosmid clone cM1, containing a fragment of the left
end of MHV-76 (13). DNA was produced from single plaques as described above
and was analyzed by using a multiplex PCR for M4 (primer pair M4AFor and
M4ARev) and ORF50 (primer pair ORF50For and ORF50Rev). Reactions
contained 50 pmol of each primer, and the cycling parameters were 94°C for 45 s,
56°C for 45 s, and 72°C for 60 s for 30 cycles, with a final extension at 72°C for
7 min. Genomic rearrangements were confirmed by Southern analysis, with the
same probes as those used to analyze MHV-76inM4.
In vitro infections. Single-step and multistep growth in vitro was analyzed by
infecting BHK-21 cells in suspension for 90 min at an MOI of 5 (single-step
growth) or 0.05 (multistep growth). Cells were pelleted and resuspended in fresh
complete Glasgow medium four times to remove unbound virus before they were
seeded into 24-well plates. At specific times p.i., wells were harvested and infec-
tious virus was determined by plaque assay, as described above. All infections
were performed in duplicate, with each infection titrated in duplicate.
Northern analysis. RNA for Northern analysis was harvested from C127 cells
infected in suspension in vitro with an MOI of 10. To inhibit early gene expres-
sion, C127 cells were treated with cycloheximide (CHX; 100 g/ml) and to inhibit
late gene expression, cells were treated with phosphonoacetic acid (PAA; 100
g/ml). CHX- and PAA-treated samples were harvested 8 h p.i. Untreated
samples were harvested 18 h p.i. RNA was extracted by using an RNeasy Minikit
(Qiagen) according to the manufacturer’s directions and then resuspended in
RNase-free water. A total of 10 g of total RNA was loaded in each lane and
fractionated through 1.2% agarose gels containing 6.6% formaldehyde, 40 mM
MOPS [3-(N-morpholino)propanesulfonic acid], 10 mM sodium acetate, and 1
mM EDTA. Blotting onto Hybond N membranes was performed in the pres-
ence of 20 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate).
32P-labeled double-stranded DNA probes specific for M4 (nt 8616 to 9176) and
ORF50 (nt 68483 to 68838) were generated from purified PCR products. Hy-
bridization was performed in Ultrahyb (Ambion) according to the manufactur-
er’s directions.
RT-PCR. Tissues used for RNA extraction were snap-frozen in liquid nitrogen
at the time of harvesting. RNA was extracted from tissues of infected BALB/c
mice by using an RNeasy Minikit (Qiagen). Briefly, after RNA isolation, RNA
was resuspended in RNase-free water and treated with 10 U of DNase I (DNA-
free; Ambion) for 1 h at 37°C. Samples were repurified by using an RNeasy kit,
and the resulting RNA was quantified by spectrophotometry (Cecil). RNA was
analyzed by denaturing gel electrophoresis to determine RNA integrity. A total
of 4 g of the resulting RNA was subjected to a final incubation with 10 U of
DNase I (DNA-free; Ambion) for 1 h at 37°C. A total of 2 g of RNA was
reverse transcribed with RNase H Superscript II (Invitrogen) in a final volume
of 20 l according to the manufacturer’s instructions. A total of 2 l of cDNA
was used per PCR, with 5 U of Taq DNA polymerase (Invitrogen) per reaction
in the presence of 100 M dNTP, 3 mM MgCl2, 50 pmol of each primer, and Taq
polymerase buffer. PCR primers used were as described by Wakeling et al. (33),
with the exception of the M4 primer pair, for which the M4AFor and M4ARev
primers were used. The cycling parameters were the same for each primer pair
set used: 94°C for 45 s, 57°C for 45 s, and 72°C for 40 s for 35 cycles, with a final
extension at 72°C for 7 min. Reverse transcription-PCR (RT-PCR) products
were separated by agarose gel electrophoresis and blotted onto Hybond N
membranes (Amersham) in the presence of 10 SSC prior to hybridization with
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32P-labeled DNA probes in Ultrahyb (Ambion) according to the manufacturer’s
directions.
Real-time PCR. Real-time PCR for the quantification of viral genome load
was performed on a LightCycler (Roche), with the intercalating dye SYBR green
to determine levels of double-stranded DNA product. A region of the ORF50
gene was amplified with specific primers (ORF50For and ORF50Rev), and all
products from real-time PCR were analyzed by melting temperature to confirm
specificity. DNA was extracted from splenocytes by using a Qiagen tissue kit, and
50 ng was used per PCR. Additional reactions were performed on a dilution
series of a plasmid containing the entire ORF50 sequence, producing a standard
curve to enable quantification of unknown samples. Standards were spiked with
DNA isolated from the spleens of uninfected BALB/c mice, demonstrating that
amplification efficiencies were comparable.
5 and 3 RACE. Rapid amplification of cDNA ends was performed as follows.
Briefly, C127 cells were infected in vitro at an MOI of 10, and harvested 18 h p.i.
RNA was extracted by using an RNeasy Minikit (Qiagen) as per manufacturers
directions, and resuspended in RNase-free water. A total of 5 g of the resulting
RNA was treated with 10 U of DNase I (DNA-free; Ambion) for 1 h at 37°C. The
resulting RNA was used directly in the First-Choice RLM-RACE (rapid ampli-
fication of cDNA ends) kit (Ambion). RACE PCR products were purified by
using a Qiagen PCR purification kit and subcloned by using the TOPO-TA
cloning kit (Invitrogen). Four reactions were sequenced for 5 RACE, and three
reactions sequenced for 3 RACE. Identical sequencing data was obtained for all
of the 5-RACE products and for all of the 3-RACE products. Sequencing was
carried out with IRD800-modified primers on a Li-Cor automated sequencer.
Statistical analysis. Titer data and real-time PCR data were analyzed by using
the nonparametric Mann-Whitney test.
RESULTS
Targeted insertion of the M4 gene. A fragment of MHV-68
spanning the predicted M4 ORF (MHV-68 sequence, nt 7414
to 10914) was selected for insertion into the left terminus of
MHV-76, in the equivalent genomic location M4 occupies in
MHV-68. This fragment contains an additional 995 bp up-
stream of the predicted M4 ORF (31), for inclusion of pro-
moter elements to allow the M4 gene to be expressed under
the control of its native promoter within MHV-76. The 3.5-kb
insert has not been shown to encode any further transcripts in
addition to M4 and does not include any sequence from the
neighboring M3 ORF. The cloned M4 sequence was compared
to the previously published sequence (31), and no base pair
alterations were detected. To assess the involvement of the M4
gene in viral pathogenesis, a recombinant MHV-76 virus ex-
pressing M4 (MHV-76inM4) was generated as described in
Materials and Methods. This resulted in a 2,125-bp insertion at
the left end of MHV-76, containing the entire predicted M4
ORF and putative promoter elements. M4 was expressed un-
der the control of its native promoter, since it was anticipated
that by this approach M4 expression by MHV-76inM4 would
reflect that of MHV-68. Furthermore, insertion of a foreign
promoter (human cytomegalovirus major immediate-early pro-
moter) has been suggested to cause inappropriate phenotypes.
Thus, inclusion of the native promoter for M4 in MHV-
76inM4 would allow for an accurate and uncomplicated anal-
ysis of the M4 gene product in vivo. After transfection and five
rounds of single-plaque selection, the MHV-76inM4 stock was
found by PCR to be homogeneous and negative for wild-type
MHV-76 (data not shown). The genomic structure of MHV-
76inM4 at the left terminus was determined by Southern anal-
ysis with purified viral DNA digested with BamHI and a double
digestion with NotI and BglII (Fig. 1). Hybridization with a
32P-labeled M4 sequence-specific probe yielded the predicted
9.8-kb fragment after BamHI digest. This fragment size
matched that expected after an 2-kb insertion in MHV-76.
FIG. 1. Construction and verification of the genomic structures of
MHV-76inM4 and MHV-76.Rev. (A) Structures of the left termini of
the genomes of MHV-68, MHV-76inM4, and MHV-76. MHV-76inM4
were generated by the insertion of the MHV-68 sequence from nt 7414
to 10914 into the equivalent region in MHV-76. MHV-76.Rev was
generated by restoring the MHV-76 sequence to MHV-76inM4, uti-
lizing a cosmid clone containing a fragment of the left terminus of the
MHV-76 genome. MHV-76 only contains the last 246 bp of the M4
ORF, whereas MHV-76inM4 contains the entire M4 ORF and puta-
tive promoter regions. The positions of restriction endonuclease sites
(Bm, BamHI; Nt, NotI; Ec, EcoRI; Bg, BglII) used to evaluate mutant
virus DNA are shown. ❋, restriction site that derives from a small
region of the polylinker site of pUC18 present within MHV-76inM4
(see Materials and Methods). (B) Southern analysis of the MHV-76,
MHV-76inM4, and MHV-76.Rev genomes. Purified MHV-76 and
MHV-76.Rev viral DNA was digested with either BamHI or
EcoRINotI, and MHV-76inM4 viral DNA was digested with either
BamHI or BglIINotI. After electrophoresis and transfer, blots were
hybridized with a 32P-labeled probe spanning the M4 region (nt 8616
to 9176) and subsequently with a probe specific for a region conserved
between each virus (nt 11099 to 16237). The results produced from
Southern hybridization matched those predicted by sequence analysis
(see Results).
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Moreover, hybridization to one distinct fragment was consis-
tent with an additional BamHI site present in MHV-76inM4.
This was as predicted, since a small region of the polylinker site
of pUC18 (between the terminal repeat and M4 fragments)
was expected to be present in MHV-76inM4. Furthermore, the
M4 probe hybridized to the expected 6.2-kb fragment from the
NotI-BglII digest. To conclusively determine the positioning of
the M4 insertion and to assess whether any undesirable
genomic rearrangements had occurred near the left terminus
of MHV-76inM4 that may not have been detected with the M4
probe, a 32P-labeled fragment of MHV-68 (HindIIIG frag-
ment, bp 11099 to 16237, MHV-68 sequence) was used for
probing. As expected, hybridization to fragments of predicted
size followed HindIIIG probing. The HindIIIG probe hybrid-
ized to a 9.8-kb fragment from the BamHI digest, matching the
results seen with the M4 probe. Furthermore, hybridization to
the predicted 5.3- and 6.2-kb fragments from the NotI-BglII
digest confirmed the M4 fragment had recombined in the cor-
rect location. The results obtained from Southern blot analysis
matched those predicted by sequence analysis exactly, verifying
that the genomic structure at the left terminus of MHV-
76inM4 was as anticipated. Finally, PCR and sequencing of
purified MHV-76inM4 DNA further demonstrated that the
insert had recombined in precisely the correct position, with no
undesirable insertions or deletions detected. Overexposure of
the blots did not indicate that any residual wild-type MHV-76
or genomically distinct subpopulation was present (data not
shown).
To exclude the possibility that any phenotype of MHV-
76inM4 was the result of a spurious mutation elsewhere in the
genome and not a direct result of the insertion of M4, a
revertant virus was generated (MHV-76.Rev). The genomic
structure at the left end of MHV-76inM4 was restored to that
of MHV-76 after cotransfection of purified MHV-76inM4
DNA with a cosmid fragment of MHV-76 (see Materials and
Methods) and subsequent selection for single plaques negative
for M4 by PCR. After transfection, a multiplex PCR-based
screening method (M4 and ORF50) was used to select for
MHV-76.Rev. Once single-plaque isolates were determined to
be negative for M4 by PCR, they were subjected to a further
three rounds of single-plaque selection to ensure homogeneity.
The viral DNA was then subject to digestion with BamHI and
a double digestion with NotI and EcoRI prior to Southern blot
analysis. Probing with a 32P-labeled M4 sequence-specific
probe yielded no detectable hybridization to either digested
MHV-76 or MHV-76.Rev DNA, validating the multiplex PCR
data. This confirmed that MHV-76.Rev contained no detect-
able M4 sequence and that the stock was free of contaminating
MHV-76inM4. The HindIIIG probe hybridized to the pre-
dicted 8.9-kb fragment from the BamHI digest, with terminal
repeat laddering visible above this size (indicative of variable
terminal repeat copy number). This banding pattern is consis-
tent with the loss of the diagnostic BamHI site in MHV-
76inM4 and further establishes that MHV-76inM4 contains an
2-kb insertion at the left end of the genome. Furthermore,
the HindIIIG probe hybridized to the expected 5- and 7.5-kb
fragments from the NotI-EcoRI digest (Fig. 1). Southern anal-
ysis of digested MHV-76 and MHV-76.Rev DNA gave indis-
tinguishable results with both probes, indicating that MHV-
76.Rev had reverted to the MHV-76 genotype.
MHV-76inM4 and MHV-76.Rev replicate equivalently in
vitro to MHV-76 and MHV-68. MHV-76 replicates indistin-
guishably from MHV-68 during single-step in vitro growth
(13), indicating that the M1, M2, M3, and M4 genes and
8vtRNA-like sequences are dispensable for in vitro replication.
As a result, it was predicted that the insertion of M4 into
MHV-76 would not influence in vitro replication. Studies on a
similar deletion mutant of MHV-68 have further established
that M4 is not essential for in vitro growth (4). Nevertheless, to
investigate whether MHV-76inM4 or MHV-76.Rev displayed
any alterations in in vitro replication, we compared MHV-
76inM4, MHV-76.Rev, MHV-76, and MHV-68 during a single
round and during multiple rounds of replication in BHK-21
cells. In our study, analysis of single and multiple rounds of
replication demonstrated that all viruses replicated equiva-
lently (Fig. 2), confirming that M4 is dispensable for in vitro
replication and does not influence cell-cell spread in vitro.
Consequently, MHV-76inM4 and MHV-76.Rev have no de-
FIG. 2. MHV-76, MHV-68, MHV-76inM4, and MHV-76.Rev rep-
licate equivalently in vitro. (A and B) Single-step growth curves (5
PFU/cell) (A) and multistep growth curves (0.05 PFU/cell) (B) were
performed to determine any growth deficiencies or enhancements in
vitro. Infected BHK-21 monolayers were harvested at specific times p.i.
and freeze-thawed three times before titers were determined by plaque
assay. The data represent the means  the standard error of the mean
(SEM), with the experiment performed in duplicate. The dashed line
represents the limit of detection of the assay (5 PFU).
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tectable differences in in vitro replication that could account
for any change in phenotype in vivo.
Characterization of M4 transcription by MHV-68 and
MHV-76inM4. The M4 ORF was originally assigned after anal-
ysis of the sequenced MHV-68 genome (31) and was predicted
to span coordinates 8409 to 9785. However, the analysis pre-
dicted putative ORFs and no studies to date have defined
whether the predicted M4 ORF corresponds to the actual M4
ORF. Of interest was the possibility of an alternative transla-
tional start site downstream of that previously predicted. By
RACE analysis, we determined the M4 transcript to initiate at
sequence 8526 and terminate at sequence 9866. Therefore,
position 8538 most likely represents the true translational start
site, since the predicted translational start site of 8409 is absent
from the transcript. This alternative ATG-initiated ORF at
position 8538 has a putative TATA box 27 bp upstream of the
beginning of the M4 transcript (position 8526). Furthermore,
this translational start site has a stricter Kozak sequence than
the previously predicted translational start site of position
8409. The above results demonstrate that the true M4 ORF
spans from positions 8538 to 9785, differing from that pre-
dicted by Virgin et al. (31).
Ebrahimi et al. (6) have previously characterized M4 as an
immediate-early transcript, expressed abundantly during lytic
replication in vitro. We sought to establish that MHV-76inM4
is capable of M4 expression and that the pattern of M4 expres-
sion from MHV-76inM4 after in vitro infection is comparable
to MHV-68. The promoter regions for M4 remain uncharac-
terized, and our inclusion of 1112 bp upstream from the tran-
scriptional start site cannot definitively ensure M4 expression
equivalent to MHV-68. Furthermore, the influence of neigh-
boring genes within MHV-68 (M1 to M3) on the regulation of
M4 expression is unknown. To exclude the possibility that the
kinetic class or level of M4 transcription differed significantly
between MHV-76inM4 and MHV-68, Northern analysis was
performed on RNA extracted from C127 cells infected in vitro
(MOI  10) (Fig. 3). CHX- and PAA-treated samples were
included to determine the kinetic class of the M4 transcripts
expressed from MHV-76inM4 and MHV-68. Hybridization
with a 32P-labeled M4 sequence-specific probe detected a dom-
inant 1.4-kb transcript from MHV-68 and MHV-76inM4
samples, but not from the MHV-76-, MHV-76.Rev-, and
mock-infected samples. M4 transcription from the CHX-
treated MHV-68 and MHV-76inM4 samples is approaching
the limit of detection of Northern analysis, since only weak
signals were detectable from these lanes after hybridization
with the M4 probe. Nevertheless, the presence of M4 expres-
sion in these samples is in agreement with previous observa-
tions that M4 can be transcribed in the absence of protein
synthesis (6). However, the distinct 1.4-kb transcript is more
abundant in the PAA-treated samples than in the CHX-
treated samples. Thus, despite limited transcription in the ab-
sence of protein synthesis, the majority of M4 transcription
requires de novo protein synthesis; we therefore propose that
M4 be classified as an immediate-early/early transcript. A 32P-
labeled ORF50 sequence-specific probe detected a distinct
2-kb band of equivalent intensity in all samples, with the
exception of the mock. This result is consistent with previous
observations of ORF50 transcription in vitro (12). Ethidium
bromide staining of the gel prior to blotting indicated that all
lanes contained equivalent amounts of rRNA (data not
shown). Probes specific for housekeeping genes (GAPDH
[glyceraldehyde-3-phosphate dehydrogenase] and 	-actin)
gave inconsistent results for RNA extracted from cells infected
with virus overnight. This is likely due to virus-induced shutoff
of host transcription as previously observed (6). Therefore,
ORF50 was used as a control for RNA loading when MHV-68
is compared with MHV-76 and mutant virus RNA. Hence,
Northern analysis shows that M4 is expressed abundantly in
vitro and that no significant differences are detectable in the
expression of M4 in vitro by MHV-68 and MHV-76inM4 with
respect to kinetic class and level of transcription.
MHV-76inM4 has increased lung titers at early times after
intranasal infection. After intranasal infection of immunocom-
petent mice, MHV-76 is cleared more rapidly from the lung
FIG. 3. Northern analysis of M4 transcription demonstrates that
M4 encodes an immediate-early mRNA. C127 cells were infected in
suspension at an MOI of 10 for 1 h (with or without inhibitors) before
incubation at 37°C for 8 h (treated samples) or 18 h (untreated sam-
ples) prior to RNA extraction. Infected cells were either left untreated,
treated with CHX (100 g/ml) to inhibit protein synthesis, or treated
with PAA (100 g/ml) to inhibit DNA synthesis. Total RNA was
harvested at the desired time p.i. and analyzed by Northern analysis.
The blot was hybridized with a 32P-labeled probe spanning the M4
region (nt 8616 to 9176), and with a 32P-labeled probe spanning the
ORF50 region (nt 68483 to 68838) to assess RNA loading and integrity
(see Results).
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than MHV-68, suggesting that at least one element at the left
terminus of MHV-68 contributes to delaying viral clearance.
To assess any role for the M4 gene product during acute
infection, BALB/c mice were infected intranasally with 4 105
PFU of virus, and viral titers were quantified by plaque assay
from lungs harvested at specific times p.i. (days 1, 5, and 7).
Figure 4 demonstrates that MHV-76inM4 was cleared from
the lungs of infected mice with kinetics similar to those of
MHV-76, as evidenced by reduced lung titers at day 7 p.i. in
comparison to MHV-68. Thus, M4 does not appear to be
involved in delaying viral clearance during productive infection
of the lung. Lung titers at day 5 p.i. were equivalent for all
viruses, establishing that MHV-76inM4 and MHV-76.Rev
were capable of producing viral titers comparable to MHV-76
and MHV-68 during the peak of productive infection (Fig. 4).
In contrast, at day 1 p.i., lung titers from MHV-76inM4-in-
fected mice were significantly elevated with respect to
MHV-76 (P  0.0006), MHV-76.Rev (P  0.0006), and
MHV-68 (P  0.0006). These findings imply that M4 is impor-
tant during the initial stages of productive infection with
MHV-68. Lung titers were analyzed between days 14 and 31 to
exclude the possibility of viral recrudescence. This was not
observed since viral titers from all mice from these time points
were below the limit of detection.
MHV-76inM4 exhibits a prolonged peak of infective centers
during acute-phase splenic latency. To assess any role for M4
during latency in vivo, we infected BALB/c mice intranasally
with 4  105 PFU of virus, and the levels of latent virus were
determined at specific times p.i. by using an ex vivo reactivation
assay. MHV-76 has a profound deficit in acute-phase splenic
latency, with M4 (absent from MHV-76) therefore a candidate
gene for contributing to viral pathogenesis during this phase of
infection. The ex vivo reactivation assay results are shown in
Fig. 5. MHV-68 infective centers were detectable from day
5 p.i. onward, with peak latency observed at day 14 p.i. In
contrast, MHV-76 infective centers peaked at day 10 p.i., with
peak latency markedly reduced with respect to MHV-68.
MHV-76inM4 infective centers peaked at day 14 p.i., although
the subsequent decline in infective centers observed with
MHV-76 infection was not evident with MHV-76inM4; the
peak level of MHV-76inM4 infective centers was maintained
throughout days 14 to 21. However, by day 100 p.i., infective
FIG. 4. MHV-76inM4 has a distinct phenotype during productive infection of the lung. BALB/c mice were infected intranasally with 4  105
PFU of virus, and lungs were harvested at day 1 (A), day 5 (B), and day 7 (C) p.i. The data shown are compiled from two (day 1) or three (days
5 and 7) independent experiments with three to four mice each. Virus titers were determined by plaque assay on BHK-21 monolayers. The data
represent the viral titers from individual mice. The dashed line represents the limit of detection of the assay (10 PFU).
FIG. 5. M4 regulates acute-phase latency in vivo. BALB/c mice
were infected intranasally with 4  105 PFU of virus, and latent virus
was determined at specific times p.i. (A) The data shown represent
latent virus (as measured by infective center assay) minus the infec-
tious virus titer. The mean number of infective centers per 107 spleno-
cytes ( the SEM) for four mice per group is shown at each time point.
(B) The mean spleen weight ( the SEM) for four mice per group is
shown for each time point. The data for both panels are from one of
two independent experiments, with similar results obtained from both
experiments.
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center data was equivalent for all viruses, suggesting that long-
term latency was established at similar levels (data not shown).
Overt splenomegaly during acute-phase latency is a well-doc-
umented phenotype accompanying MHV-68 infection (3, 8,
23), and this process has been demonstrated to increase the
peak level of infective centres following MHV-68 infection
(25). Splenomegaly is significantly reduced with MHV-76 in-
fection in comparison to MHV-68 infection. Despite obvious
differences in the patterns of acute-phase latency associated
with MHV-76 and MHV-76inM4 infection, no evidence of
significant splenomegaly was detectable with either virus, pre-
dicting little or no role for M4 in enhancing splenomegaly (Fig.
4).
MHV-76inM4 has an increased latent viral DNA load in the
spleen. To confirm that the phenotype of MHV-76inM4 during
acute-phase latency (as observed by reactivation assay) was the
result of a difference in the level of latent virus and not solely
due to an alteration in reactivation efficiency, real-time PCR
was performed to quantify the viral genome load in splenocytes
at days 14, 17, 21, and 31 p.i. The same splenocyte samples
were used for both the reactivation assay and real-time PCR to
allow a meaningful analysis. A portion of ORF50 was selected
for amplification since it occupied a region distal to that af-
fected by mutagenesis. The results are shown in Fig. 6. Melting
analysis showed a specific melting peak for each sample at
86°C, which corresponded to a distinct product of expected
size after agarose gel electrophoresis (data not shown). At all
time points analyzed, the spleens of MHV-76inM4-infected
mice contained greater levels of latent viral DNA than
MHV-76 or MHV-76.Rev. Specifically, at days 17 and 21 p.i.,
the difference in MHV-76inM4 viral genome load is statisti-
cally significant with respect to MHV-76 and MHV-76.Rev
(day 17, P 
 0.029; day 21, P 
 0.029). Thus, a positive
correlation between viral DNA copy number and reactivation
assay data was observed at days 14 to 21 p.i. However, it is
interesting that at day 17 p.i. MHV-68 and MHV-76inM4
differ considerably by reactivation assay and yet have equiva-
lent viral genome copy numbers as determined by real-time
PCR analysis.
M4 expression in vivo is detectable during lytic infection but
not during persistence. To establish the pattern of M4 expres-
sion in vivo and whether such expression is compatible with the
in vivo phenotype of MHV-76inM4, RT-PCR was performed
on lung and spleen tissues from MHV-68-, MHV-76inM4-, and
MHV-76.Rev-infected mice (Fig. 7). Expression in the lung
was investigated at days 2, 4, and 14 p.i., encompassing both
the acute-phase and resolution of productive infection. M4
expression in the spleen was analyzed at days 14, 21, and
100 p.i., covering both acute-phase latency and long-term per-
sistence. Primers specific for the genes M4, ORF50, M11, and
murine 	-actin were used for analysis. ORF50 is only tran-
FIG. 6. MHV-76inM4 has an increased latent viral DNA load in
the spleen in comparison to MHV-76. BALB/c mice were infected
intranasally with 4  105 PFU of virus, and total DNA was extracted
from splenocytes harvested at specific times p.i. Quantification of viral
genomes was performed by real-time PCR analysis by using a Light-
Cycler (Roche), with primers specific for the MHV-68 ORF50 gene.
The mean copy number of viral genomes ( the SEM) for four mice
per group is shown for each time point.
FIG. 7. In vivo transcription of M4. RNA was extracted from the lungs and spleens of BALB/c mice (two mice per virus per time point) at
specific times p.i. RT-PCR was performed with primer sets specific for viral genes (M4, ORF50, and M11), in addition to murine 	-actin. To
confirm specificity, RT-PCR products were electrophoresed and subject to Southern blot analysis with 32P-labeled gene-specific probes. For each
RNA sample, reverse transcriptase was omitted in one case to control for the carryover of DNA (M11, no RT) prior to PCR and Southern blot
analysis.
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scribed during lytic infection, whereas M11 transcription has
been detected during lytic infection and persistence (18, 33).
	-Actin expression was abundant in all tissue samples, and
control reactions performed without RT were uniformly neg-
ative. The sensitivity was determined by limiting dilution of
PCR products generated with external primers and was deter-
mined to be between 1 and 10 copies in all cases. ORF50
expression by MHV-76inM4 at day 2 p.i. appeared more abun-
dant in comparison to MHV-68 and MHV-76.Rev. This find-
ing is consistent with plaque assay results establishing that
MHV-76inM4-infected mice have elevated viral titers at this
stage of infection. M4 was consistently detected during lytic
infection in the lung from all MHV-76inM4 and MHV-68-
infected mice but, within the spleen, M4 expression was less
consistent; M4 expression was detectable in only one of two
MHV-76inM4-infected mice at days 14 and 21 and in two of
two MHV-68-infected mice at day 14. However, no M4 expres-
sion was detectable within the spleen at day 21 in MHV-68-
infected mice. Importantly, M4 expression was always accom-
panied with ORF50 expression, which is in agreement with
previous data demonstrating that M4 is not a latency-associ-
ated transcript (32). The presence of M4 transcription at day
100 p.i. in one MHV-76inM4-infected mouse is presumably the
result of spontaneous reactivation or persistent low-level rep-
lication since ORF50 expression is evident. Thus, M4 expres-
sion by MHV-76inM4 and MHV-68 is consistently expressed
during productive infection of the lung but is not consistently
detectable during acute-phase splenic latency.
DISCUSSION
We have assessed here the role for the M4 gene product in
vivo via a novel approach to MHV-68 mutagenesis. Insertion
of the M4 gene into a deletion mutant of MHV-68 (MHV-76)
produced a recombinant gammaherpesvirus (MHV-76inM4)
expressing M4 similarly to MHV-68 in vitro, with a distinct
phenotype during both productive infection in the lung, and
during acute-phase latency in the spleen after intranasal infec-
tion of BALB/c mice. MHV-76inM4 exhibits elevated viral
titers during productive infection in the lungs at 24 h p.i. and
displays an increased latent load in the spleen during acute-
phase latency compared to MHV-76. In addition, we have
characterized the M4 transcript, characterizing both the initi-
ation and termination sites of M4 transcription, and the tem-
poral expression pattern in vitro.
Phenotype of MHV-76inM4 during productive infection in
vivo. Preliminary sequence analysis of the MHV-68 genome
led to the assignment of the putative M4 ORF. The genomic
location of M4 and the absence of any obvious homolog led to
the prediction that M4 may be important during infection in
vivo (31). Two deletion mutants of MHV-68 lacking various
elements, including the M4 ORF, replicate identically to
MHV-68 in vitro, a finding consistent with the hypothesis that
M4 is involved in pathogenesis in vivo (4, 13). Previous studies
have detected M4 transcription during lytic infection in vivo
but not during latent infection (20, 32). Our study is in agree-
ment with such findings, since we were only able to detect M4
coexpressed with ORF50, a marker of lytic replication. How-
ever, we cannot exclude the possibility that M4 is expressed as
a latent transcript by specific cell populations during acute-
phase latency, whereas lytic replication is ongoing in different
cell types. This is a possible scenario, since recent data dem-
onstrate that M4 is expressed by several B-cell populations
during acute-phase latency in the absence of ORF50 expres-
sion; in contrast, M4 expression by dendritic cells and macro-
phages was accompanied by ORF50 expression (14). Never-
theless, our data predict that M4 is not involved in the
maintenance of long-term latent infection. It is not surprising
that MHV-76inM4 exhibits a phenotype during productive in-
fection of the lung, since M4 expression is readily detectable at
this site during this phase of infection. MHV-76inM4 exhibits
10-fold-higher lung titers at day 1 p.i. compared to MHV-76.
This demonstrates that M4 plays an important role shortly
after intranasal infection, possibly targeting an innate immune
mechanism, such as alpha/beta interferons, macrophages/
monocytes, natural killer cells or  T cells; the expression of
M4 as an immediate-early transcript may be important for this
early activity. It is interesting that MHV-68 does not exhibit an
increase in viral titers 24 h p.i. compared to MHV-76, given
that MHV-68 expresses M4 in a similar fashion to MHV-
76inM4 at this time. However, since M1, M2, and M4 and the
8vtRNA-like sequences have not yet been functionally charac-
terized, their influence on viral pathogenesis is unknown, par-
ticularly if expressed independently of one other. Thus, the
combined effects of several gene products during the early
phases of infection may explain the phenotypic differences
between MHV-68 and MHV-76inM4 at 24 h p.i., since MHV-
76inM4 lacks several elements present in MHV-68. Consider-
ing the intimate herpesvirus-host relationship, a more vigorous
productive infection may not be advantageous, in evolutionary
terms, to MHV-68; it may be detrimental to the host, jeopar-
dizing the long-term carriage of the virus. M3, a soluble che-
mokine-binding protein encoded by MHV-68 but not MHV-
76inM4, is expressed abundantly during productive infection
and thus may have a role in influencing the early stages of
productive infection. A recombinant vaccinia virus with a non-
functional chemokine-binding protein exhibited significantly
increased viral titers in vivo compared to the wild-type strain,
demonstrating that specific viral immunoregulatory elements
suppress maximal viral replication and virulence (17). Despite
a possible elevation in ORF50 expression in MHV-76inM4-
infected mice at day 2 p.i., it seems unlikely that an increase in
ORF50 expression (which could enhance lytic replication) is
responsible for the observed elevation in lung titers, since an
accompanying elevation in M4 expression was also detectable,
especially after gel electrophoresis of the PCR products prior
to blotting (data not shown). Importantly, in vitro replication
was equivalent for all viruses, with no detectable enhancement
of MHV-76inM4 replication. A simpler explanation is that the
increased viral titers and increased ORF50 expression are both
markers of an enhanced productive infection.
Phenotype of MHV-76inM4 during acute-phase latency in
the spleen. Since M4 was not readily detectable as a latency-
associated transcript, it is interesting that MHV-76inM4 dem-
onstrated a phenotype during acute-phase latency. The in-
crease in infective centers from MHV-76inM4-infected mice at
days 14 to 21 p.i., with respect to MHV-76, was in good agree-
ment with the levels of latent viral genome copy number in the
splenocyte population. Thus, MHV-76inM4 exhibits an ele-
vated latent viral load in the spleen. In view of the reactivation
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assay data, MHV-76inM4-infected mice most likely have an
increased frequency of virus genome-positive cells in the
spleen compared to MHV-76. However, one limitation of the
real-time PCR analysis is that it was unable to determine the
frequency of genome-positive splenocytes to unequivocally
confirm this. Thus, the data suggest that M4 may be necessary
for a maximal peak latent load during MHV-68 infection. One
explanation for this phenotype is that a specific immune mech-
anism is responsible for the observed decline in infective cen-
ters with MHV-76 between days 10 and 14 p.i. If the M4 gene
product inhibits the action of this immune mechanism, MHV-
76inM4 would exhibit delayed clearance from the spleen. An
alternative explanation, although one that we consider less
likely given the phenotype in the lung, is that the phenotype in
the spleen is the result of M4 actively contributing to the
proliferation of latently infected cells, resulting in an increased
latent load in spite of ongoing immune clearance. The stage of
infection that the M4 gene product mediates its effect is un-
known. The first possibility is that the M4 protein is having an
effect at the times the phenotype is evident; however, M4
expression was variable between mice at the times the pheno-
type was observed. Therefore, M4 may only be produced in
small amounts during acute-phase latency, suggesting that the
M4 protein would have to be active in small quantities. A
second explanation is that M4 may be an inherently stable
protein able to persist in the splenic environment, having been
produced principally during the establishment of splenic la-
tency when lytic replication is more prevalent. If M4 does have
immunomodulatory properties, this hypothesis suggests that
the control of both productive and latent infection share a
common immune mediator. Finally, it is conceivable that the
phenotype observed in the spleen is the result of M4 expres-
sion during productive infection from a distal site other than
the spleen. Expression of M4 within the lung or in the medi-
astinal lymph nodes draining the lung could result in an in-
creased number of latently infected cells that may subsequently
traffic to the spleen and give rise to an increased latent load.
Control of reactivation during acute-phase latency. It is
clear that multiple factors influence the reactivation efficiency
ex vivo. Previous studies have implicated virus-specific ele-
ments in the control of reactivation ex vivo; deletion mutants
of MHV-68 frequently exhibit altered reactivation efficiencies
ex vivo in comparison to wild-type MHV-68 (4, 5, 15). Fur-
thermore, the observation that certain immune mechanisms
appear to influence ex vivo reactivation implies host factors
play a role in determining reactivation phenotype (24). In the
present study, we observed differences in reactivation efficiency
between MHV-68 and MHV-76inM4. Specifically, at day
17 p.i., the splenic viral latent loads of the two viruses are
equivalent, whereas the reactivation efficiencies differed by
7-fold. Given the close correlation between the reactivation
assay and real-time PCR data, it seems likely that the differ-
ence in reactivation efficiency between MHV-68 and MHV-
76inM4 observed at this time reflects an inherent ability of
MHV-68 to reactivate better than MHV-76inM4 during acute-
phase latency. Considering the different genomic structures of
MHV-68 and MHV-76inM4, some element at the left terminus
of MHV-68, other than M4, may augment reactivation effi-
ciency during acute-phase latency. An MHV-68 mutant with a
large deletion at the left terminus reactivates less efficiently
from splenocytes during acute-phase latency than does
MHV-68 (4). This finding is consistent with an element at the
left end of MHV-68 having a role in altering reactivation ef-
ficiency.
MHV-68, between days 14 to 21 p.i., exhibits a decrease in
viral latent load that mirrors the ex vivo reactivation data. This
reduction in viral latent load (and reactivation) likely repre-
sents immune clearance of latent MHV-68. Conversely, MHV-
76inM4 exhibits an increase in viral latent load between days
14 and 17 p.i. Since MHV-76 does not exhibit a significant
decline in latent load akin to MHV-68, this rapid decline in
viral latent load appears to be a feature of MHV-68 infection.
It is possible that the higher latent load in splenocytes from
MHV-68-infected mice elicits a greater immune response than
MHV-76inM4, resulting in a more rapid eradication of latently
infected splenocytes. Furthermore, only MHV-68 displays sig-
nificant splenomegaly, and it is not known whether this ampli-
fication of lymphocytes influences the immune response to
MHV-68. The M2 gene of MHV-68 is latency associated, is
expressed predominantly by B lymphocytes during splenomeg-
aly, and is a target for CD8 T cells (10). This could explain
why MHV-76inM4 does not display a reduction in viral load
between days 14 to 17, particularly if M2-specific CD8 T cells
are found to be important for controlling MHV-68 during
acute-phase latency. Alternatively, the differences between
MHV-76inM4 and MHV-68 may reflect different states of
latency. We consider it unlikely that the splenic phenotype
associated with MHV-76inM4 is predominantly due to the
establishment of latency in a different cell population from
MHV-76, since it has been demonstrated that the vast majority
of both latent MHV-76 and MHV-68 is present within the
CD19-B-lymphocyte population (13). This indicates that the
elements at the left end of MHV-68, absent in MHV-76, do not
play a significant role in determining cellular tropism in the
spleen.
At days 21 to 31 p.i., there is a significant decrease in reac-
tivation observed with both MHV-68 and MHV-76inM4 with-
out an equivalent decrease in viral latent load. We had origi-
nally predicted this decrease in reactivation to be the result of
immune-mediated clearance of latently infected cells; how-
ever, real-time PCR data suggest otherwise. It has been pro-
posed that specific immune mechanisms (gamma interferon in
particular) are capable of influencing ex vivo reactivation effi-
ciency (24), and this is one possibility that may explain the
observed phenotype. Alternatively, the decrease in reactivation
efficiency may simply reflect a transition to a more stable form
of latency. It is noteworthy that latent virus recovered during
acute-phase latency reactivates more efficiently than latent vi-
rus from mice in which long-term latency is established (34).
One possibility is the existence of multiple latency programs,
akin to Epstein-Barr virus, in which distinct patterns of gene
expression can be identified during latency. Although no la-
tency programs have been characterized for MHV-68, it does
appear that several forms of latency exist in vivo (26, 28).
In conclusion, the data show that M4 is expressed as an
immediate-early/early transcript and is expressed predomi-
nantly during productive infection in vivo. M4 modulates both
productive infection in the lung at early times p.i. and levels of
latent virus during acute-phase latency. This finding supports a
possible role for M4 in immunoregulation, with the available
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data suggesting that M4 may interfere with an innate immune
mechanism. The functional characterization of M4 is currently
under way in our laboratory.
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